Physicochemical Properties
| Molecular Formula | C30H51N5O7 |
| Molecular Weight | 593.75524 |
| Exact Mass | 593.379 |
| CAS # | 2503-26-6 |
| PubChem CID | 11124817 |
| Appearance | White to off-white solid powder |
| Density | 1.17g/cm3 |
| Boiling Point | 875ºC at 760mmHg |
| Flash Point | 483ºC |
| Vapour Pressure | 4.15E-31mmHg at 25°C |
| Index of Refraction | 1.535 |
| LogP | 1.787 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 5 |
| Heavy Atom Count | 42 |
| Complexity | 1020 |
| Defined Atom Stereocenter Count | 6 |
| SMILES | CC[C@H](C)[C@H]1C(=O)N([C@H](C(=O)N([C@H](C(=O)NCCC(=O)O[C@@H](C(=O)N2CCC[C@H]2C(=O)N1)CC(C)C)C)C)C(C)C)C |
| InChi Key | GNBHVMBELHWUIF-VTSYCQLTSA-N |
| InChi Code | InChI=1S/C30H51N5O7/c1-10-19(6)24-29(40)34(9)25(18(4)5)30(41)33(8)20(7)26(37)31-14-13-23(36)42-22(16-17(2)3)28(39)35-15-11-12-21(35)27(38)32-24/h17-22,24-25H,10-16H2,1-9H3,(H,31,37)(H,32,38)/t19-,20-,21-,22+,24-,25-/m0/s1 |
| Chemical Name | (3R,10S,13S,16S,19S)-16-[(2S)-butan-2-yl]-10,11,14-trimethyl-3-(2-methylpropyl)-13-propan-2-yl-4-oxa-1,8,11,14,17-pentazabicyclo[17.3.0]docosane-2,5,9,12,15,18-hexone |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Destruxin B (1-30 μM; 48 hours) suppresses H1299 and A549 cells' ability to proliferate, with IC50 values of 4.1 μM and 4.9 μM, respectively [1]. The apoptosis inducible by Destruxin B (1-30 μM; 48 hours) in A549 cells is largely due to the activation of the mitochondria-dependent caspase cascade [1]. In a time- and dose-dependent manner, destruxin B (1.25-20.00 μM; 72 hours) therapy dramatically reduced the viability of HT-29 human colorectal cancer cells [2]. A549 cells treated with destruxin B (10 or 20 μM; 12 and 24 hours) showed a concentration- and time-dependent increase in the pro-apoptotic protein PUMA and a decrease in the anti-apoptotic protein Mcl-1 [1]. |
| ln Vivo | In a dose- and time-dependent way, Destruxin B (DB) (injection; 0.6–15 mg/kg/day for 6 weeks) inhibits the growth of tumors [2]. |
| Cell Assay |
Cell proliferation experiment [1] Cell Types: H1299 cells Tested Concentrations: 1, 5, 10, 20, 30 μM Incubation Duration: 48 hrs (hours) Experimental Results: Inhibits H1299 cell proliferation, IC50 is 4.1 μM. Apoptosis analysis [1] Cell Types: Lung adenocarcinoma A549 cells Tested Concentrations: 1,5,10,20,30 μM Incubation Duration: 48 hrs (hours) Experimental Results: Induced caspase-dependent lung adenocarcinoma A549 cell death. Cell viability assay [2] Cell Types: HT-29 human colorectal cancer cells Tested Concentrations: 1.25, 2.50, 5.00, 10.00 and 20.00 μM Incubation Duration: 72 hrs (hours) Experimental Results: The IC50 measured at 24 hrs (hours), 48 hrs (hours) and 72 hrs (hours) was 14.97, 2.00 and 0.67 μM respectively. Western Blot Analysis[1] Cell Types: A549 Cell Tested Concentrations: 10 or 20 μM Incubation Duration: 12 and 24 hrs (hours) Experimental Results: Regulation of Mcl-1 and PUMA. |
| Animal Protocol |
Animal/Disease Models: Athymic female nude mice (BALB/cAnN.Cg-Foxn1nu/CrlNarl), approximately 4-5 weeks old on arrival [2] Doses: low dose (0.6 mg/kg), medium dose (3 mg/kg) , High dose (15 mg/kg) Route of Administration: injection; daily; lasted for 6 weeks. Experimental Results: Low dose, medium dose and high dose demonstrated a reduction of 23.9%, 33.4% and 55.8% in average tumor size, respectively. |
| References |
[1]. Destruxin B Isolated from Entomopathogenic Fungus Metarhizium anisopliae Induces Apoptosis via a Bcl-2 Family-Dependent Mitochondrial Pathway in Human NonsmallCell Lung Cancer Cells. Evid Based Complement Alternat Med. 2013;2013:548929. [2]. In vitro and in vivo anticancer effects of destruxin B on human colorectal cancer. Anticancer Res. 2012 Jul;32(7):2735-45. |
| Additional Infomation | Unii-7R6CR62kfe has been reported in Metarhizium indigoticum, Metarhizium anisopliae, and Alternaria brassicae with data available. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6842 mL | 8.4209 mL | 16.8418 mL | |
| 5 mM | 0.3368 mL | 1.6842 mL | 3.3684 mL | |
| 10 mM | 0.1684 mL | 0.8421 mL | 1.6842 mL |